Improving rate of decline of FEY1 in young adults with cystic fibrosis

Que, C.; Cullinan, P.; Geddes, D.
February 2006
Thorax;Feb2006, Vol. 61 Issue 2, p155
Academic Journal
Background: CF is characterised by a progressive decline in lung function; reductions in this decline are often used as a measure of success in clinical trials. With improvements in treatment it may be that there has been a temporal shift in the pattern of the disease. Methods: 318 patients born in five successive cohorts and attending a specialist clinic with at least two routine measurements of lung function made between the ages of 18 and 22 were included. The declines in their lung function were estimated and compared. Results: The mean (SE) slopes for percentage predicted forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were -1.53 (0.36)% and -1.27 (0.34)%, respectively (NS). The annual deterioration in FEV1 was -2.49%, -1.99% -2.20%, -1.65%, and -0.65% from the earliest to the most recent birth cohort; a similar pattern was observed for changes in FVC. There were no differences between male and female patients. Patients infected with Pseudomonas had a greater average decline in FEV1 (-1.6% v -1.1%). Conclusions: The rates of decline in lung function in young adults with CF have diminished with successive birth cohorts. This has important implications for the design of clinical studies in this disease.


Related Articles

  • Longitudinal Development of Mucoid Pseudomonas aeruginosa Infection and Lung Disease Progression in Children With Cystic Fibrosis. Li, Zhanhai; Kosorok, Michael R.; Farrell, Philip M.; Laxova, Anita; West, Susan E. H.; Green, Christopher G.; Collins, Jannette; Rock, Michael J.; Splaingard, Mark L. // JAMA: Journal of the American Medical Association;2/2/2005, Vol. 293 Issue 5, p581 

    Context Although Pseudomonas aeruginosa is the most common virulent respiratory pathogen in cystic fibrosis (CF), the longitudinal development of P aeruginosa infection and its effect on antibody responses and lung disease progression in children with CF remain unclear. Objective To...

  • DISCOVERY AEROSOLIZED KL-4 SURFACTANT SELECTED FOR PHASE 2A.  // Biotech Business;Oct2008, Vol. 21 Issue 10, p6 

    The article reports that Discovery Laboratories, Inc. has announced that its proprietary, aerosolized KL-4 surfactant has been selected for a Phase 2a clinical trial in patients with Cystic Fibrosis (CF). This trial is designed to evaluate the safety and tolerance in patients with mild to...

  • Mechanical airway clearance using the Frequencer electro-acoustical transducer in cystic fibrosis. Cantin, AndreĆ© M.; Bacon, Mare; Berthiaume, Yves // Clinical & Investigative Medicine;Jun2006, Vol. 29 Issue 3, p159 

    Purpose. Clearance of mucus from airways is the cornerstone of therapy for lung disease in patients with cystic fibrosis (CF). This paper describes the operation of the Frequencer, a novel respiratory physiotherapy device comprised of an electro-acoustical transducer. We hypothesized that the...

  • KaloBios: a step forward to tackling unmet needs in CF.  // PharmaWatch: Monthly Review;May2008, Vol. 7 Issue 5, p34 

    The article discusses the start of the clinical trial of KB001, an antibody fragment for the treatment of Pseudomonas aeruginosa infections by KaloBios Pharmaceuticals Inc. in the U.S. The author states that patients with cystic fibrosis often experience lung infections and that pathogens may...

  • Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and new treatments. Brugha, Rossa E; Davies, Jane C // British Journal of Hospital Medicine (17508460);Nov2011, Vol. 72 Issue 11, p614 

    The article offers information on cystic fibrosis, and discusses the pathogenic mechanisms of Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. It explains how the organism P. aeruginosa establishes an infection and develops into a biofilm. The article also discusses the new...

  • Pseudomonas serolo9y: confusion, controversy, and challenges. Farrell, P. M.; Govan, J. R. W. // Thorax;Aug2006, Vol. 61 Issue 8, p645 

    The author reflects on the issue regarding the diagnostic value of pseudomonas serology in cystic fibrosis. A paper published in the journal illustrate the controversy and challenge that have become important with regards to pseudomonas serology in cystic fibrosis. Furthermore, the pioneering...

  • Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Taccetti, Giovanni; Bianchini, Elisa; Cariani, Lisa; Buzzetti, Roberto; Costantini, Diana; Trevisan, Francesca; Zavataro, Lucia; Campana, Silvia // Thorax;Oct2012, Vol. 67 Issue 10, p853 

    Background Pseudomonas aeruginosa chronic pulmonary infection is an unfavourable event in cystic fibrosis. Bacterial clearance is possible with an early antibiotic treatment upon pathogen isolation. Currently, no best practice exists for early treatment. The efficacy of two different regimens...

  • The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections. Driscoll, James A.; Brody, Steven L.; Kollef, Mann H. // Drugs;2007, Vol. 67 Issue 3, p351 

    Pseudomonas aeruginosa is an important bacterial pathogen, particularly as a cause of infections in hospitalised patients, immunocompromised hosts and patients with cystic fibrosis. Surveillance of nosocomial P. aeruginosa infections has revealed trends of increasing antimicrobial resistance,...

  • Monitoring Respiratory Disease Severity in Cystic Fibrosis. Davies, Jane C.; Alton, Eric W. F.W. // Respiratory Care;May2009, Vol. 54 Issue 5, p606 

    Measurements of disease severity provide a guide for the physician to tailor therapies, for the patient and family to gauge progress, and are required for clinical trials. For many respiratory diseases, including cystic fibrosis, sensitive, noninvasive measurements are few. and ,some of those...


Read the Article


Sign out of this library

Other Topics